New npj Parkinson’s Disease publication, building on the previously reported Hybridopa™ Phase IIa results, demonstrates for the first time, that behaviourally driven brain plasticity likely enhances the efficacy of dopaminergic treatment and provides both clinical and neurobiological benefits These findings further strengthen the mechanistic and translational rationale of Hybridopa™ and support its progression toward a Phase III clinical trial

NEW YORK, July 1, 2026 /PRNewswire/ — Remepy, a pioneer in Hybrid Drugs™, today announced the publication of new mechanistic findings in npj Parkinson’s Disease (Nature Portfolio). The study provides insight, for the first time, into how Hybridopa™, Remepy’s Hybrid Drug for the treatment of Parkinson’s disease, may enhance the motor improvements previously observed and reported in Remepy’s Phase IIa trial, through multimodal digital interventions, that combine evidence-based training activities with neuroscience-informed tools aimed at promoting brain plasticity.

The publication builds on Remepy’s Phase IIa clinical and neuroimaging findings recently published in Brain Communications, which showed significant improvements in motor and non-motor outcomes in levodopa-treated patients receiving Hybridopa™ compared with levodopa and a placebo app, alongside measurable changes in brain networks involved in movement and mood regulation. The newly published findings extend this evidence by adding a complementary neuroimaging approach using diffusion tensor imaging (DTI), which assesses changes in white matter structure rather than brain function alone. Together, the two studies provide converging functional and structural evidence that Hybridopa™ engages motor-related brain circuits associated with the observed clinical improvements.

“Our Phase IIa trial showed that Hybridopa™ delivers meaningful clinical improvements for people living with Parkinson’s disease,” said Or Shoval, Co-Founder and Co-CEO of Remepy. “This publication helps explain the neural mechanisms underlying those effects. We demonstrate, for the first time, that combining levodopa with precisely structured, personalized, multimodal digital interventions is associated with measurable changes in brain structure and function that align with improved clinical outcomes. This mechanistic insight supports the development of a first-in-class Hybrid Drug for Parkinson’s disease.”

The research was conducted in collaboration with Reichman University, highlighting a strong industry–academic partnership in translational neuroscience.

“Parkinson’s disease involves more than dopamine deficiency. It reflects dysfunction across distributed brain networks,” said Prof. Amir Amedi, Chief Science Officer, Remepy, and a professor at Reichman University. “Our findings suggest that a structured, multimodal approach engaging motor, cognitive, emotional, and sensory systems may help modulate these networks and promote neuroplastic changes that complement pharmacological treatment.”

“The combined clinical and mechanistic evidence, supported by advanced imaging techniques and rigorous analysis, strengthens the scientific foundation for Remepy as it prepares to initiate a global Phase III trial of Hybridopa™ later this year,” added Dr. Michal Tsur, Co-Founder and Co-CEO of Remepy. “Together, these findings support a shift in Parkinson’s treatment toward integrated approaches that combine pharmacological therapy with structured, system-level digital interventions. We now have a much deeper understanding of the effects of combining structured, non-pharmacological interventions with levodopa. This growing body of clinical and mechanistic evidence, supported by advanced imaging techniques and rigorous analysis, is what motivates us to advance Hybridopa™ into Phase III later this year.”

Using three different types of brain scans, researchers found consistent evidence that Hybridopa™ was associated with changes in a key brain region involved in controlling movement. Participants who used Hybridopa™ showed less intact brain fibers in this region, stronger communication with other movement-related areas, and more efficient activity across the brain networks that support movement. Importantly, these brain changes were accompanied by meaningful improvements in standard clinical measures of Parkinson’s symptoms. The study also found that the more participants engaged with Remepy’s training program, the greater their clinical improvement, suggesting a strong link between digital therapy, changes in the brain, and better motor function.

This is the first study to show that multiple advanced brain imaging techniques independently identified the same brain changes following a digital therapeutic intervention for Parkinson’s disease. Remarkably, these changes emerged within just a few weeks in a brain region that is known to be affected by Parkinson’s. The findings provide new evidence that targeted digital training may help the brain adapt by strengthening and reorganizing its neural connections, even in the presence of a progressive neurodegenerative disease. The results also support the growing view that digital therapeutics can complement medication by promoting the brain’s natural ability to change and learn, a process known as neuroplasticity.

About Hybridopa™

Hybridopa™, for the treatment of Parkinson’s disease, combines immediate-release levodopa/carbidopa with DopApp™, a therapeutic protocol delivered through a mobile application. Hybridopa™ adapts to patient performance, behavior, and clinical status to enhance both motor and non-motor symptoms in Parkinson’s disease. Currently, Phase III ready, Hybridopa™ is an investigational product and has not yet been approved by the FDA or any regulatory authority.

About Remepy

Remepy is a clinical-stage biotechnology company pioneering Hybrid Drugs™, a new class of drugs combining traditional drugs with personalized, AI-driven therapeutic apps. Remepy partners with leading pharma companies to bring to market Hybrid Drugs, that integrate pharmacology with adaptive physical, cognitive, and behavioral interventions into a single treatment, enabling scalable, multidisciplinary care within a standard drug prescription model. Supported by emerging FDA frameworks for drug–software combination products and strong clinical data, this model is rapidly gaining traction. Remepy’s lead program, Hybridopa™ for Parkinson’s, is entering Phase III following strong Phase IIa results. Remepy is turning drugs into intelligent, software-enabled, adaptive treatment platforms. For additional information, please visit: https://www.remepy.com/  

For media inquiries, please contact:

Tsipi Haitovsky
Global Media Liaison
Remepy
Press@remepy.com

View original content:https://www.prnewswire.com/news-releases/remepy-publishes-new-evidence-showing-its-hybrid-drug-hybridopa-effect-on-structural-connectivity-in-the-brain-of-parkinsons-patients-associated-with-improved-clinical-outcome-302815701.html

SOURCE Remepy

NEW YORK, July 1, 2026 /PRNewswire/ — Nuveen, a global investment leader managing $1.4 trillion in assets under management1, today announced the closing of a $546 million preferred equity investment in SunZia, the largest renewable energy infrastructure project in U.S. history that is now fully operational. The investment was made through Nuveen Energy Infrastructure Credit (EIC), the firm’s infrastructure credit investment platform and underscores continued large-scale investment momentum in the American clean energy sector and represents a landmark transaction in clean and critical infrastructure.

At $546 million, this is Nuveen EIC’s largest preferred tax equity allocation to date and serves as the cornerstone for the platform’s preferred investment strategy, which Nuveen EIC is launching to provide flexible, scalable capital to the developers building the nation’s most consequential energy infrastructure. In total, Nuveen EIC’s (alongside its coinvestors’) commitments to SunZia approached $1.5 billion across four investments, reflecting the firm’s deep conviction in Pattern Energy’s expertise and sophistication to manage a project of this scale and magnitude and do so on-time and on-budget.

Developed by Pattern Energy, SunZia comprises a 3,650-megawatt (MW) wind project and a 550-mile high-voltage direct current (HVDC) transmission line delivering low-cost, American-made energy from New Mexico to Arizona and to customers across the western grid. The project generates and delivers more power than the Hoover Dam and, at full capacity, will deliver enough energy to power approximately one million American homes annually. By pairing large-scale generation with interregional transmission, SunZia addresses one of the central challenges facing the energy sector: not only building energy generation, but also the grid infrastructure needed to deliver that power across the country.

“SunZia represents exactly the kind of consequential infrastructure our platform was built to finance,” said Don Dimitrievich, Head of Nuveen Energy Infrastructure Credit. “We are proud to partner with Pattern Energy on the largest clean energy project in U.S. history, and to anchor our new preferred investment strategy with a landmark transaction of this scale. This investment reflects our conviction that disciplined, flexible capital can help bring the nation’s most ambitious energy projects to life at the speed and volume the current moment demands.”

Nuveen EIC is a leading investor in clean energy and infrastructure finance, bringing deep market expertise and a shared commitment to accelerating U.S. clean energy deployment. The EIC platform provides flexible financing structures, ranging from credit facilities and structured debt and equity solutions to preferred tax equity investments. The firm partners with management teams and equity sponsors to support project development, construction, and long-term asset ownership.

“SunZia represents a new standard for delivering large-scale energy infrastructure,” said Kenji Ogawa, SVP of Project Finance at Pattern Energy. “We’re pleased to partner with Nuveen EIC on this milestone investment, which reflects strong market confidence in the project’s fundamentals and execution. Transactions like this are essential to scaling the energy infrastructure needed today, and we’re proud to help advance that model through SunZia.”2

Milbank LLP served as legal advisor to Nuveen EIC. Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisor to Pattern Energy.

ABOUT NUVEEN

Nuveen, a TIAA Company, is a global investment leader, managing $1.4 trillion in public and private assets for clients around the world, as of March 31, 2026. With broad expertise across income and alternatives, we invest in the growth of businesses, real estate, infrastructure, and natural capital, providing clients with the reliability, access, and foresight unique to our 125+ year heritage. Our prevailing perspective on the future drives our ambition to innovate and adapt our business to the changing needs of investors — all to pursue lasting performance for our clients, our communities, and our global economy. For more information, please visit www.nuveen.com.

Infrastructure investments of the type described herein are subject to material risks that could adversely affect performance and returns, including project operating and transmission risk, counterparty risk, changes in applicable regulations or tax law (including the reduction, recapture, or disallowance of anticipated tax benefits), and market and power-price fluctuations. There can be no assurance that the investment described herein will achieve its objectives or that projected results will be realized. Past performance is not indicative of future results.

This transaction may not be representative of all investments or outcomes in the strategy.

This material is not intended to be a recommendation or investment advice, does not constitute a solicitation to buy, sell or hold a security or an investment strategy, and is not provided in a fiduciary capacity. The information provided does not take into account the specific objectives or circumstances of any particular investor, or suggest any specific course of action. Investment decisions should be made based on an investor’s objectives and circumstances and in consultation with his or her advisors.

Nuveen, LLC provides investment solutions through its investment specialists

Investing involves risk; loss of principal is possible.

Concentration in infrastructure-related securities involves sector risk and concentration risk, particularly greater exposure to adverse economic, regulatory, political, legal, liquidity, and tax risks associated with MLPs and REITs.

The investment transactions presented herein are a subset of the strategy’s overall investments and no single investment is representative of the strategy or its operations as a whole. It should not be assumed that any investment has been or will be profitable and is not a guarantee of investment performance or outcomes.

1 All figures as of March 31, 2026
2 This testimonial was provided by a current client of Nuveen, and no direct or indirect compensation was given in return. No material conflicts of interest exist on the part of the individual giving the testimonial, resulting from their relationship with the adviser. Results experienced by individual may not be representative of the experience of other clients, and there is no guarantee of future performance or success.

Media Contact:
Andrew Chironna
Andrew.Chironna@nuveen.com
212-913-1015 – (CIT)

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuveen-energy-infrastructure-credit-completes-546m-preferred-equity-investment-in-sunzia-the-largest-clean-energy-project-in-us-history-302815157.html

SOURCE Nuveen

Lab deepens Reju’s scientific capabilities, bridging innovation with commercial-scale solutions

PARIS and CONSHOHOCKEN, Pa., July 1, 2026 /PRNewswire/ — Reju, the textile-to-textile materials regeneration company, today announced that it had opened a Research & Development Center in Conshohocken, Pennsylvania, marking the company’s first dedicated research facility in North America. Located within Technip Energy’s Advanced Materials and Catalysts’ existing research center, the lab will help Reju accelerate the deployment of its recycling technologies and will help develop Reju’s next-generation circular solutions.

The R&D Center marks the relocation of Reju’s core research team from IBM’s Almaden Research Center in San Jose, California, where Reju’s Volcat depolymerizaztion technology, a catalytic chemical recycling method breaking down polyester into reusable raw materials, was first developed.

“I am excited to be joining such an innovative company and to be part of the team moving the technology towards industrialization and supporting the infrastructure for true post-consumer textile-to-textile recycling at scale,” said Gregory Breyta, Reju’s Director of Research & Development.

The facility will be focused on the full development spectrum, from early-stage feasibility through to kilo-scale production. It will span polyester recycling, mixed-fabric solutions, and new circular chemistry pathways, enabling rapid iteration and accelerating Reju’s path from concept to industrial reality. The new R&D center will support the development and validation of technologies intended for deployment across Reju’s future Regeneration Hubs.

By locating the facility within Technip Energies’ existing research infrastructure, Reju will benefit from direct access to decades of Technip Energies’ expertise in catalysis, process development, technology integration and industrial scale-up.

The establishment of the R&D Center is a component of Reju’s broader strategy to build a closed-loop recycling ecosystem that converts discarded fabric and textiles back into quality products. The center joins Reju’s growing global infrastructure, including their first textile-to-textile facility Regeneration Hub Zero in Frankfurt, Germany and future Regeneration Hubs that have been announced in Sittard (Netherlands), Lacq (France), and Rochester, New York (USA).

“Together, these facilities form a replicable global circular infrastructure designed to turn today’s textile waste into tomorrow’s raw materials,” said Breyta.

About Reju

Reju is a materials regeneration company focused on creating innovative solutions for regenerating polyester textiles and post-consumer PET waste. Owned by Technip Energies and utilizing technology originating with IBM Research, Reju is driven by its purpose to unlock infinite possibilities within finite resources. The company aims to establish a global textile recycling circular system to regenerate and recirculate polyester textiles. Learn more at https://www.reju.com/.

About Technip Energies

Technip Energies is a global technology and engineering powerhouse. With leadership positions in LNG, hydrogen, ethylene, sustainable chemistry, and CO2 management, we are contributing to the development of critical markets such as energy, energy derivatives, decarbonization, and circularity. Our complementary business segments, Technology, Products and Services (TPS) and Project Delivery, turn innovation into scalable and industrial reality.

Through collaboration and excellence in execution, our 18,000+ employees across 35 countries are fully committed to bridging prosperity with sustainability for a world designed to last.

Technip Energies generated revenues of €7.2 billion in 2025 and is listed on Euronext Paris. The Company also has American Depositary Receipts trading over the counter.

For further information: www.ten.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/reju-opens-first-us-research–development-center-in-conshohocken-pennsylvania-302815039.html

SOURCE Reju